Ghrelin Hormone May Alleviate Cellular Stress in Gestational Diabetes

Gestational Diabetes Mellitus (GDM) is a common pregnancy complication characterized by high blood sugar, increasing risks for both mother and baby. Cellular stress, particularly endoplasmic reticulum (ER) stress, is increasingly recognized as a key contributor to the development and progression of GDM by impairing insulin sensitivity and pancreatic beta-cell function. This study investigates how ghrelin, a hormone known for regulating appetite and metabolism, influences the ER stress signaling pathway in the context of GDM.

The study found that ghrelin significantly modulated ER stress markers in both models. In high-glucose treated placental cells, ghrelin treatment led to a 45% reduction in the expression of key ER stress markers like GRP78 and CHOP (p<0.001), compared to untreated cells. Furthermore, it restored insulin signaling, showing a 2.3-fold increase in Akt phosphorylation (p<0.01). In the GDM mouse model, ghrelin administration resulted in a 28% decrease in fasting blood glucose levels (p<0.05) and a 35% improvement in glucose tolerance tests compared to control GDM mice. The most significant finding was that ghrelin treatment in GDM mice led to a 60% reduction in placental ER stress protein levels and a 52% decrease in inflammatory cytokine production (p<0.001), indicating a broad protective effect against GDM-associated pathology.